WESTCHESTER, Ill., Nov. 22 /PRNewswire/ -- BrainLAB, a worldwide leading innovator in image-guided medical technology, and Varian Medical Systems, today announced the extension of their global supply and distribution agreement for the Novalis and m3 products. The agreement extends through 2010, reflecting the strong commitment by both companies to bring the most advanced solutions in cancer therapy to clinicians and patients.
Novalis is a dedicated, software driven neurosurgery technology, which is able to treat both benign and malignant tumors, AVMs and functional disorders with single or multi-fractionation and IMRT. Novalis systems are used to treat thousands of patients each year, for a wide range of indications including cancers of the brain, head and neck, spine, liver, lung and prostate. BrainLAB's continuous focus on software innovation and strong partnerships with industry leaders, such as Varian Medical Systems, keeps Novalis at the forefront of technology.
"Novalis systems are used to treat thousands of patients around the world each year, for a wide range of indications including cranial, lung, liver, and spine cancer. Our continuous focus on software innovation and strong partnerships with industry leaders, such as Varian Medical Systems, keeps Novalis at the forefront of technology," said Stefan Vilsmeier, CEO and Founder of BrainLAB. "This partnership agreement is great news for our clinicians who know and trust that both companies are committed to design, build and sell the best radiosurgery and radiotherapy products and services."
"From the inception of the Novalis technology, we have enjoyed a strong and ongoing partnership with BrainLAB, wherein Varian Medical Systems' linear accelerator and multi-leaf collimator technology play critical roles in a system designed for advanced radiosurgical treatments," said Timothy Guertin, President and Chief Operating Officer of Varian Medical Systems. "We are pleased to continue supporting BrainLAB in its effort to provide hospitals with robust clinical solutions for their patients."
About BrainLAB
BrainLAB, a privately held company headquartered in Munich, Germany, was founded in 1989 and is specialized in the development, manufacture, and marketing of medical technology for radiosurgery / radiotherapy, orthopedics, neurosurgery, and ENT. Among the products developed by BrainLAB are software and hardware components for image-guided surgery and radiotherapy as well as integrated systems for stereotactic radiosurgery. With 1,990 systems installed in over 65 countries, BrainLAB is among the market leaders in image-guided medical technology. BrainLAB today employs 670 people worldwide and has 15 offices across Europe, Asia, North and South America.
For more information, visit BrainLAB at http://www.brainlab.com .
About Varian
Varian Medical Systems, Inc., of Palo Alto, California is the world's leading manufacturer of integrated cancer therapy systems, which are treating thousands of patients per day. The company is also a premier supplier of X- ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,571 people who are located at manufacturing sites in North America and Europe and in its 55 sales and support offices around the world. In its most recent fiscal year ended September 30, 2005, Varian Medical Systems reported sales of $1.4 billion.
Additional information on Varian Medical Systems may be obtained on the company's website: http://www.varian.com .
BrainLABCONTACT: Gabriella Cyranski, Marketing Communications Manager, of BrainLABInc., +1-708-486-0114, cell, +1-312-771-7200,gabriella.cyranski@brainlab.com ; or Spencer Sias, Vice President,Corporate Communications and Investor Relations, of Varian Medical Systems,+1-650-424-5782, spencer.sias@varian.com
